Malignant hyperthermia

Overview 
Theory 
Diagnosis 
Management 
Follow up 
Resources 

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Última revisão: 24 Sep 2025

Última atualização: 08 Oct 2025

Malignant hyperthermia (MH) is a potentially lethal syndrome usually triggered by inhalation anesthetics and/or succinylcholine.

The underlying genetic susceptibility is most often due to a range of autosomal dominant mutations in RYR1, although CACNA1S and STAC3 are also implicated.

Caused by an increase in metabolic rate driven by an increase in intracellular calcium levels in muscle.

Presents with increased carbon dioxide production, muscle rigidity, tachycardia, hyperthermia, and mixed metabolic and respiratory acidosis.

A definitive diagnosis requires testing after the acute episode has resolved. Genetic testing may be the first test performed in selected patients; it may form part of the autopsy if MH is suspected as the cause of death. A muscle biopsy contracture test can be used to exclude susceptibility to MH.

The mainstay of treatment includes discontinuation of the triggering agent, administration of intravenous dantrolene, and restoration/maintenance of normal core temperature.

Rhabdomyolysis, acute kidney injury, hyperkalemia, and disseminated intravascular coagulation are frequently seen.

If the diagnosis is confirmed, all blood relatives should be contacted since the disease is autosomal dominant with variable penetrance and testing for the condition may be indicated.

Definição

MH is a syndrome that typically follows exposure to potent inhalation anesthetics and/or succinylcholine in susceptible individuals.[1][2]Larach MG, Dirksen SJ, Belani KG, et al; Society for Ambulatory Anesthesiology; Malignant Hyperthermia Association of the United States; Ambulatory Surgery Foundation; Society for Academic Emergency Medicine; National Association of Emergency Medical Technicians. Special article: creation of a guide for the transfer of care of the malignant hyperthermia patient from ambulatory surgery centers to receiving hospital facilities. Anesth Analg. 2012 Jan;114(1):94-100. In MH susceptible patients this exposure may produce a clinical MH episode: a dramatic increase in metabolism, which leads to critical temperature elevation and rhabdomyolysis with potential hyperkalemia. In the absence of central core disease, susceptibility to MH is a subclinical condition. However, some MH-susceptible people may feel uncomfortable exercising in the heat, and complaints of muscle cramps are not uncommon.[3]

História e exame físico

Principais fatores diagnósticos

exposure to potent inhalation anesthetic and/or succinylcholine
susceptibility to malignant hyperthermia (MH)
previous malignant hyperthermia (MH) episode
positive family history
increased minute ventilation
elevated core temperature
muscle rigidity

Detalhes completos

Outros fatores diagnósticos

tachycardia
decreased urine output
excessive sweating with exercise
muscle cramps
spontaneous episodes of severe muscle stiffness

Detalhes completos

Fatores de risco

exposure to potent inhalation anesthetic and/or succinylcholine
susceptibility to Malignant hyperthermia (MH)
previous malignant hyperthermia (MH) episode
positive family history
exertional heat illness

Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

discontinuation of inhalation anesthetic
exhaled carbon dioxide, oxygen consumption (inspired-expired oxygen concentration difference)
venous blood gases
serum electrolytes
serum creatinine
therapeutic trial of intravenous dantrolene
creatine kinase
urinalysis
urine myoglobin
platelets
prothrombin time

Detalhes completos

Investigações a serem consideradas

caffeine halothane contracture test (CHCT)
in vitro contracture test (IVCT)
genetic testing
screen for muscle enzyme deficiencies

Detalhes completos

Algoritmo de tratamento

AGUDA

inhalation anesthetic-induced

exercise- or heat-induced

Colaboradores

Autores

Christopher M. Edwards, MD

Assistant Professor

Department of Anesthesiology

University of Florida College of Medicine

Gainesville

Declarações

CME declares that he has no competing interests.

Nikolaus Gravenstein, MD

Professor

Department of Anesthesiology

University of Florida College of Medicine

Gainesville

Declarações

NG is a medical adviser/consultant for Teleflex, and has co-developed anesthesia patient safety education courses.

Agradecimentos

Christopher M Edwards and Nikolaus Gravenstein would like to gratefully acknowledge Dr Barbara W. Brandom and Dr Lena Mayes, the previous contributors to this topic.

Declarações

LM declares that she has no competing interests. BWB has been reimbursed by the not-for-profit sponsor of the North American MH Registry (NAMHR), the Malignant Hyperthermia Association of the United States (MHAUS) for attending meetings related to the management of the NAMHR. BWB was the unpaid director of the NAMHR, until Jul 2016. BWB is also an author of a number of references cited in this topic.

Revisores

Henry Rosenberg, MD

Director

Department of Medical Education and Clinical Research

Saint Barnabas Medical Center

Livingstone

Declarações

HR declares that he has no competing interests.

Philip Hopkins, MD

Professor of Anesthesia

University of Leeds

Academic Unit of Anesthesia

St James's University Hospital

Leeds

Declarações

PH is an author of a number of references cited in this topic.

Thierry Girard, MD

Associate Professor

Perioperative Patient Safety

Department of Biomedicine

University Hospital Basel

Basel

Switzerland

Disclosures

TG declares that he has no competing interests.

Joseph Tobin, MD, FAAP, FCCM

Professor and Chairman

Department of Anesthesiology

Wake Forest University School of Medicine

Winston-Salem

Disclosures

JT is an author of a number of references cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: guideline from the Association of Anaesthetists. Anaesthesia. 2021 May;76(5):655-64.Full text Abstract

Larach MG, Dirksen SJ, Belani KG, et al; Society for Ambulatory Anesthesiology; Malignant Hyperthermia Association of the United States; Ambulatory Surgery Foundation; Society for Academic Emergency Medicine; National Association of Emergency Medical Technicians. Special article: creation of a guide for the transfer of care of the malignant hyperthermia patient from ambulatory surgery centers to receiving hospital facilities. Anesth Analg. 2012 Jan;114(1):94-100.Full text Abstract

Rüffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021 Jan;126(1):120-30.Full text Abstract

European Malignant Hyperthermia Group. Recognising and managing a malignant hyperthermia crisis (v2024). Nov 2024 [internet publication].Full text

Litman RS, Smith VI, Larach MG, et al. Consensus statement of the Malignant Hyperthermia Association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth Analg. 2019 Apr;128(4):652-9. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Nonmalignant hyperthermia rhabdomyolysis
- Muscle disuse atrophy
- Myotonia
More Differentials
Guidelines
- Recognizing and managing a malignant hyperthermia crisis
- Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group
More Guidelines
Log in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer

Malignant hyperthermia

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

Outros fatores diagnósticos

Fatores de risco

Investigações diagnósticas

Primeiras investigações a serem solicitadas

Investigações a serem consideradas

Algoritmo de tratamento

inhalation anesthetic-induced

exercise- or heat-induced

Colaboradores

Autores

Christopher M. Edwards, MD

Declarações

Nikolaus Gravenstein, MD

Declarações

Agradecimentos

Declarações

Revisores

Henry Rosenberg, MD

Declarações

Philip Hopkins, MD

Declarações

Thierry Girard, MD

Disclosures

Joseph Tobin, MD, FAAP, FCCM

Disclosures

Peer reviewer acknowledgements

Disclosures

References

Key articles

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials

Guidelines

Log in or subscribe to access all of BMJ Best Practice

Log in or subscribe to access all of BMJ Best Practice

Log in to access all of BMJ Best Practice